Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

In Europe, as in US, climate for embryo stem cell research is one of extremes

Article Abstract:

Scientists in US and Europe are facing highly polarized opinions about whether embryo stem cell should be permitted and an equally divergent range of political support for funding it. The federal funding in US is permitted only for research using a limited number of embryonic stem cell lines generated before 2001 and the European Commission, gives limited funds for stem cell research, though the EU's 25 member nations are allowed to implement their own regulations.

Author: Bosch, Xavier
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Europe, Research grants, Research funding, Stem cells

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


European researchers team up to probe genetic, environmental links in dyslexia

Article Abstract:

Researchers from nine European countries are working together to determine the relation between genetic, neuroscientific and behavioral factors and dyslexia, a complex learning disorder in children that affects reading and spelling. The US research groups are expressing interest in creating a transatlantic project on dyslexia in correlation with this Neurodys project funded by the European Commission.

Author: Bosch, Xavier
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2006
Financial management, Finance, Dyslexia, European Union. European Commission, Company financing

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


European researchers, drug companies join forces against rare diseases

Article Abstract:

European Rare Diseases Therapeutic Initiative (ERDITI), a team of European Academic Research institutions and pharmaceutical companies is developed to promote the evaluation of compounds that are abandoned by drug companies. The need is felt, as most companies cannot justify the cost of traditional pharmaceutical research, including screening of compounds and preclinical development.

Author: Bosch, Xavier
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Usage, Economic aspects, Drug therapy, Genetic disorders, Pharmaceutical research, Orphan drugs

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States
Similar abstracts:
  • Abstracts: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. Intensive insulin therapy and pentastarch resuscitation in severe sepsis
  • Abstracts: Senescence comes of age. Roots and stems: Stem cells in cancer. Telomeres and telomerase: The path from maize, tetrahymena and yeast to human cancer and aging
  • Abstracts: Cord blood stem cell network proposed. Internet seen as clinical research tool. Meth lab fires put heat on burn centers
  • Abstracts: Does the metabolic syndrome really exist?: Diabetes and heart disease groups spar over issue. Heart groups issue advisories for reducing drug-eluting stent risks
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.